Skip to content Skip to footer

BPC157 Peptide: Mechanism, Research Applications and Handling Requirements

The BPC157 peptide is a synthetic pentadecapeptide, a linear chain of 15 amino acids, modelled on a fragment of a protein first isolated from human gastric juice. In laboratory research it is studied for its reported effects on endothelial cell signalling, tendon fibroblast behaviour and the integrity of gastrointestinal tissue in rodent injury models. It is supplied as a lyophilised powder for in-vitro and preclinical investigation only. This article covers its structure and origins, the proposed mechanisms, four areas of published research, and the purity, storage and handling standards that matter when sourcing it for the laboratory.

What is the BPC157 peptide?

BPC 157 takes its name from “Body Protection Compound”. The 15-residue sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular formula of C62H98N16O22 and a molecular weight of approximately 1419.5 g/mol. Three consecutive proline residues near the N-terminus give the molecule a constrained backbone, which is usually cited as one reason it is comparatively stable in acidic conditions relative to many short peptides.

The compound was developed and characterised mainly by a research group at the University of Zagreb in Croatia, led by Predrag Sikirić, beginning in the early 1990s. The parent protein was identified in gastric juice, and the 15-amino-acid fragment was selected because it retained activity in experimental models while being easy to synthesise. In the older literature the peptide appears under designations such as PL 14736 and Bepecin, and current papers write it as BPC 157, BPC-157 or BPC157.

Regulatory status is worth stating plainly. In the United Kingdom, BPC 157 has no marketing authorisation from the MHRA and is not an approved medicine. It is also not permitted in sport under the World Anti-Doping Agency rules. For laboratory purposes it is classed as a research chemical, and its use is confined to in-vitro work and ethically approved preclinical studies.

Mechanism of action

The mechanism of BPC 157 has not been fully resolved. No single, high-affinity receptor has been definitively identified, and the published explanations are best understood as a set of overlapping signalling observations rather than one settled pathway.

The most frequently cited observation involves vascular endothelial growth factor receptor 2 (VEGFR2). In cultured endothelial cells, exposure to the peptide has been reported to increase VEGFR2 expression and to activate downstream signalling through the Akt and endothelial nitric oxide synthase (eNOS) axis. This is the pathway most often linked to the pro-angiogenic behaviour described in animal tissue models, including increased vessel formation in ischaemia and wound studies.

A second line of work concerns tendon-derived fibroblasts. In cell culture, BPC 157 was associated with increased expression of the growth hormone receptor and with activation of JAK2 signalling, alongside greater cell proliferation. Separate experiments describe effects on the FAK-paxillin pathway, which governs cell adhesion and migration, and this is thought to underlie the enhanced outgrowth and migration of tendon cells observed in vitro.

A third area is the nitric oxide system. Several rodent studies describe the peptide modulating nitric oxide synthesis and interacting with both NOS inhibitors and NO precursors, although how these results should be interpreted remains debated. Other proposed actions include effects on dopaminergic and serotonergic systems in rodent behavioural models and changes in early growth response gene expression.

This breadth is both the interest and the difficulty. A compound that appears to touch several signalling networks makes it hard to attribute a given result to one target, and the mechanistic literature should be treated as provisional until independent groups replicate the key findings with defined controls.

What the research shows

The evidence base is predominantly preclinical, and a large share of it comes from a single research network. That is a limitation in itself, and independent replication remains thin. Four areas of work are summarised below, without any implication that findings in animals or cultured cells transfer to people.

The first area is tendon and soft-tissue models. Studies in rats examined transected Achilles tendon and compared treated animals with controls using histological and functional measures. A separate in-vitro study by Chang and colleagues, published in the Journal of Applied Physiology, examined cultured tendon fibroblasts and described effects on outgrowth, survival and migration. A follow-up from the same group reported increased growth hormone receptor expression in these cells. Records for this work can be found through a PubMed search on BPC 157 and tendon fibroblasts. In the rodent experiments reviewed, the Zagreb group typically reported administering the peptide at doses on the order of 10 µg/kg or 10 ng/kg, by intraperitoneal injection or in drinking water, depending on the model.

The second area is angiogenesis. Work using endothelial cell cultures and a rat hindlimb ischaemia model reported activation of VEGFR2 signalling and increased vessel formation. Because pro-angiogenic signalling is a point of interest in many experimental contexts, researchers generally note that these studies are not a substitute for formal toxicological or carcinogenicity testing. Relevant records can be located through a PubMed search on BPC 157 and VEGFR2.

The third area is the gastrointestinal work that formed the original research programme. Rat models of gastric and intestinal lesions and of anastomosis healing were used to study tissue integrity. The outcomes were reported as histological and macroscopic measures, and this stream of work is the oldest and the most extensively published.

The fourth area is the very limited human literature. A handful of small pilot or retrospective reports exist, and an early phase I programme for a related formulation was reportedly begun, but results from large registered randomised trials are not available in the peer-reviewed record. For this reason, the BPC157 peptide is described in the literature as an investigational research compound, and its safety and efficacy in humans have not been established.

Across all four areas, the studies tended to be short, to use small groups and to focus on tissue-level outcomes rather than systematic safety endpoints. They are useful for generating hypotheses and for designing in-vitro experiments, but they should not be read as evidence of any therapeutic effect.

Research applications

In the laboratory, BPC 157 is used as a tool compound in a small number of experimental settings. In cell culture, it is applied to endothelial cells, tendon-derived fibroblasts and gut epithelial lines to study migration, proliferation, tube formation and intracellular signalling. In scratch and wound-closure assays, it serves as a test article against which migration rates under defined conditions can be compared.

In preclinical animal research, it appears in models of tendon, ligament and muscle injury, gastrointestinal lesions and vascular occlusion. Work of this kind requires institutional ethical review and, in the United Kingdom, a licence under the Animals (Scientific Procedures) Act 1986 where applicable.

In analytical chemistry, the peptide is also used as a reference material for method development. Its defined sequence and proline-rich structure make it a convenient test case for reversed-phase HPLC separations and for mass spectrometry workflows, including studies of fragmentation behaviour in proline-rich sequences. Laboratories validating peptide purity assays sometimes use it as a model analyte for this reason.

All of these applications are in-vitro or preclinical. Nothing in the existing literature supports extrapolation to human use.

Purity, storage and handling

For a peptide with limited independent characterisation, the quality of the material is a first-order variable in any experiment. A contaminated or mis-synthesised batch can produce artefacts that are easily mistaken for biological effects, so analytical verification is the foundation of reproducible work.

High-performance liquid chromatography (HPLC) is the standard method for assessing peptide purity, and research-grade BPC 157 is generally expected to reach 98% or higher by this measure. HPLC establishes how much of the sample is the main component, but it does not confirm identity. A credible certificate of analysis therefore also includes mass spectrometry confirming the expected molecular mass of approximately 1419.5 Da. Residual trifluoroacetic acid content, water content and, for cell-based work, endotoxin testing are further parameters worth requesting. The certificate should be batch-specific and carry a batch number that matches the vial, because a generic or recycled certificate says nothing about the lot actually received.

Stability is the second consideration. Although the proline-rich sequence gives the peptide some resilience, it remains a peptide, and degradation accelerates once it is in solution. Because of this, batch-level HPLC verification matters more here than with more stable compounds. UK laboratories sourcing the bpc157 peptide or comparing suppliers to buy best peptides for related assays should expect a batch-specific certificate of analysis and lyophilised storage at -20°C.

Lyophilised powder is typically stable for extended periods at -20°C when kept sealed, dry and protected from light. Short-term storage at 2 to 8°C is commonly tolerated during transit. Vials should be allowed to reach room temperature before opening, which prevents condensation and moisture uptake. Once reconstituted in sterile or bacteriostatic water for laboratory use, solutions are generally held at 2 to 8°C and used within a short window. Repeated freeze-thaw cycles should be avoided, so preparing single-use aliquots is standard practice. Prolonged exposure to light should also be avoided. Standard laboratory personal protective equipment applies, and handling should follow the institution’s chemical risk assessment.

Frequently asked questions

What is the BPC 157 amino acid sequence?

BPC 157 is a 15-residue peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its molecular formula is C62H98N16O22 and its molecular weight is approximately 1419.5 g/mol. Mass spectrometry on a batch certificate should confirm a mass consistent with this value.

How pure should research-grade BPC 157 be?

Research-grade material is generally expected to reach at least 98% purity by HPLC, with mass spectrometry confirming identity. Because impurities can distort experimental results, a batch-specific certificate of analysis that matches the vial’s batch number is more informative than a headline purity figure on a product page.

How should lyophilised BPC 157 be stored?

Lyophilised BPC 157 is generally stored sealed at -20°C, protected from light and moisture. Once reconstituted, solutions are usually kept at 2 to 8°C and used within a short period. Single-use aliquots help avoid repeated freeze-thaw cycles. Researchers should always follow the batch documentation and institutional protocols.

Is BPC 157 approved as a medicine in the UK?

No. BPC 157 has no MHRA marketing authorisation and is not an approved medicine in the United Kingdom. It is supplied as a research chemical for laboratory use. Large, registered human clinical trials have not been completed, so the evidence base remains largely preclinical.

Conclusion

This compound is supplied for in-vitro laboratory research only. It is not for human or veterinary use, and nothing in this article should be read as guidance on administration, dosing or therapeutic benefit.

Leave a comment

99% Purity Guarantee
Trusted By Researchers
★★★★★
Celebrating 500,000 Orders
Third party verified